Eyepoint Pharmaceuticals Stock Total Debt

EYPT Stock

USD 8.53 0.19 2.18%

Eyepoint Pharmaceuticals fundamentals help investors to digest information that contributes to Eyepoint Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eyepoint Stock. The fundamental analysis module provides a way to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyepoint Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

Total Debt To Capitalization is likely to drop to 0.02 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eyepoint Pharmaceuticals Company Total Debt Analysis

Eyepoint Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Eyepoint Pharmaceuticals Total Debt

4.91 M

Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Eyepoint Total Debt Driver Correlations

Understanding the fundamental principles of building solid financial models for Eyepoint Pharmaceuticals is extremely important. It helps to project a fair market value of Eyepoint Stock properly, considering its historical fundamentals such as Total Debt. Since Eyepoint Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eyepoint Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eyepoint Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Short Term Investments	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Long Term Debt Total	Short Long Term Debt	Capital Stock
Total Assets		0.99	-0.96	-0.85	0.18	0.88	1.0	0.51	-0.18	0.66	0.81	-0.2	0.65	-0.23	0.92	0.85	0.79	0.4	1.0	1.0	0.58	-0.73	-0.76
Total Stockholder Equity	0.99		-0.98	-0.77	0.07	0.79	0.99	0.38	-0.29	0.55	0.78	-0.16	0.54	-0.19	0.93	0.86	0.72	0.3	0.98	0.99	0.47	-0.61	-0.69
Net Debt	-0.96	-0.98		0.74	0.02	-0.73	-0.96	-0.34	0.36	-0.48	-0.74	0.15	-0.46	0.17	-0.89	-0.82	-0.71	-0.28	-0.95	-0.96	-0.38	0.57	0.65
Retained Earnings	-0.85	-0.77	0.74		-0.46	-0.92	-0.83	-0.65	-0.19	-0.77	-0.78	0.51	-0.8	0.53	-0.79	-0.71	-0.89	-0.62	-0.84	-0.82	-0.71	0.85	0.82
Net Receivables	0.18	0.07	0.02	-0.46		0.46	0.14	0.51	0.83	0.54	0.61	-0.17	0.63	-0.17	0.18	0.39	0.53	0.43	0.21	0.17	0.68	-0.55	-0.55
Total Liab	0.88	0.79	-0.73	-0.92	0.46		0.85	0.78	0.15	0.88	0.77	-0.28	0.88	-0.3	0.75	0.7	0.86	0.62	0.87	0.85	0.79	-0.96	-0.84
Total Current Assets	1.0	0.99	-0.96	-0.83	0.14	0.85		0.45	-0.22	0.62	0.8	-0.19	0.61	-0.21	0.94	0.86	0.78	0.37	0.99	1.0	0.54	-0.69	-0.75
Intangible Assets	0.51	0.38	-0.34	-0.65	0.51	0.78	0.45		0.35	0.81	0.49	-0.27	0.75	-0.29	0.34	0.35	0.62	0.58	0.49	0.44	0.68	-0.87	-0.55
Common Stock	-0.18	-0.29	0.36	-0.19	0.83	0.15	-0.22	0.35		0.26	0.28	-0.31	0.32	-0.3	-0.13	0.06	0.25	0.34	-0.16	-0.2	0.32	-0.28	-0.26
Accounts Payable	0.66	0.55	-0.48	-0.77	0.54	0.88	0.62	0.81	0.26		0.59	-0.25	0.92	-0.27	0.48	0.47	0.72	0.66	0.67	0.62	0.88	-0.93	-0.56
Property Plant Equipment	0.81	0.78	-0.74	-0.78	0.61	0.77	0.8	0.49	0.28	0.59		-0.17	0.64	-0.19	0.79	0.95	0.83	0.41	0.83	0.82	0.58	-0.68	-0.83
Current Deferred Revenue	-0.2	-0.16	0.15	0.51	-0.17	-0.28	-0.19	-0.27	-0.31	-0.25	-0.17		-0.22	1.0	-0.18	-0.13	-0.24	-0.29	-0.17	-0.16	-0.2	0.25	0.19
Long Term Debt	0.65	0.54	-0.46	-0.8	0.63	0.88	0.61	0.75	0.32	0.92	0.64	-0.22		-0.24	0.46	0.45	0.76	0.79	0.67	0.62	0.94	-0.91	-0.72
Short Term Debt	-0.23	-0.19	0.17	0.53	-0.17	-0.3	-0.21	-0.29	-0.3	-0.27	-0.19	1.0	-0.24		-0.2	-0.15	-0.26	-0.3	-0.2	-0.18	-0.22	0.27	0.2
Short Term Investments	0.92	0.93	-0.89	-0.79	0.18	0.75	0.94	0.34	-0.13	0.48	0.79	-0.18	0.46	-0.2		0.88	0.74	0.21	0.91	0.93	0.4	-0.57	-0.71
Net Tangible Assets	0.85	0.86	-0.82	-0.71	0.39	0.7	0.86	0.35	0.06	0.47	0.95	-0.13	0.45	-0.15	0.88		0.76	0.22	0.87	0.87	0.4	-0.57	-0.73
Capital Surpluse	0.79	0.72	-0.71	-0.89	0.53	0.86	0.78	0.62	0.25	0.72	0.83	-0.24	0.76	-0.26	0.74	0.76		0.65	0.8	0.78	0.65	-0.85	-0.81
Deferred Long Term Liab	0.4	0.3	-0.28	-0.62	0.43	0.62	0.37	0.58	0.34	0.66	0.41	-0.29	0.79	-0.3	0.21	0.22	0.65		0.44	0.38	0.58	-0.71	-0.49
Net Invested Capital	1.0	0.98	-0.95	-0.84	0.21	0.87	0.99	0.49	-0.16	0.67	0.83	-0.17	0.67	-0.2	0.91	0.87	0.8	0.44		1.0	0.58	-0.73	-0.76
Net Working Capital	1.0	0.99	-0.96	-0.82	0.17	0.85	1.0	0.44	-0.2	0.62	0.82	-0.16	0.62	-0.18	0.93	0.87	0.78	0.38	1.0		0.54	-0.69	-0.75
Long Term Debt Total	0.58	0.47	-0.38	-0.71	0.68	0.79	0.54	0.68	0.32	0.88	0.58	-0.2	0.94	-0.22	0.4	0.4	0.65	0.58	0.58	0.54		-0.81	-0.67
Short Long Term Debt	-0.73	-0.61	0.57	0.85	-0.55	-0.96	-0.69	-0.87	-0.28	-0.93	-0.68	0.25	-0.91	0.27	-0.57	-0.57	-0.85	-0.71	-0.73	-0.69	-0.81		0.76
Capital Stock	-0.76	-0.69	0.65	0.82	-0.55	-0.84	-0.75	-0.55	-0.26	-0.56	-0.83	0.19	-0.72	0.2	-0.71	-0.73	-0.81	-0.49	-0.76	-0.75	-0.67	0.76

Click cells to compare fundamentals

Eyepoint Total Debt Historical Pattern

Today, most investors in Eyepoint Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eyepoint Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eyepoint Pharmaceuticals total debt as a starting point in their analysis.

Eyepoint Pharmaceuticals Total Debt

Timeline

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Competition

Predict Eyepoint Pharmaceuticals

Short Long Term Debt Total Over Time

Eyepoint Short Long Term Debt Total

Short Long Term Debt Total

5.36 Million

At this time, Eyepoint Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year.

Based on the latest financial disclosure, Eyepoint Pharmaceuticals has a Total Debt of 4.91 M. This is 99.82% lower than that of the Pharmaceuticals sector and 98.49% lower than that of the Health Care industry. The total debt for all United States stocks is 99.91% higher than that of the company.

Eyepoint Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.

Eyepoint Pharmaceuticals is currently under evaluation in total debt category among its peers.

Eyepoint Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Eyepoint Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Eyepoint Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eyepoint Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eyepoint Pharmaceuticals' value.

		Shares
Patient Square Capital	2024-09-30	1.4 M
T. Rowe Price Investment Management,inc.	2024-09-30	1.3 M
State Street Corp	2024-09-30	1.2 M
Goldman Sachs Group Inc	2024-09-30	1.2 M
Geode Capital Management, Llc	2024-09-30	1.2 M
Octagon Capital Advisors Lp	2024-09-30	1.1 M
5am Venture Management, Llc	2024-09-30	1.1 M
Perceptive Advisors Llc	2024-09-30	1 M
Tcg Crossover Management, Llc	2024-09-30	922.3 K
Cormorant Asset Management, Llc	2024-09-30	8.3 M
Suvretta Capital Management, Llc	2024-09-30	5.2 M

Eyepoint Fundamentals

	Return On Equity	-0.75
	Return On Asset	-0.31
	Profit Margin	(2.27) %
	Operating Margin	(3.11) %
	Current Valuation	363.28 M
	Shares Outstanding	68.25 M
	Shares Owned By Insiders	1.14 %
	Shares Owned By Institutions	93.79 %
	Number Of Shares Shorted	10.34 M
	Price To Earning	(2.82) X
	Price To Book	2.72 X
	Price To Sales	13.17 X
	Revenue	46.02 M
	Gross Profit	(64.48 M)
	EBITDA	(69 M)
	Net Income	(70.8 M)
	Cash And Equivalents	171.17 M
	Cash Per Share	5.02 X
	Total Debt	4.91 M
	Debt To Equity	0.30 %
	Current Ratio	6.16 X
	Book Value Per Share	4.09 X
	Cash Flow From Operations	1.88 M
	Short Ratio	11.39 X
	Earnings Per Share	(1.99) X
	Target Price	33.42
	Number Of Employees	121
	Beta	1.52
	Market Capitalization	601.97 M
	Total Asset	355.18 M
	Retained Earnings	(742.15 M)
	Working Capital	281.54 M
	Current Asset	15.08 M
	Current Liabilities	11.26 M
	Net Asset	355.18 M

About Eyepoint Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC